Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing ...

Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - - First quarter sales of Symvess® were ...

Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY Anticipated Dispensing Commencement and Flora Sync LF5 Commercial Launch Summer 2026 ...

QT Imaging Holdings, Inc. (Nasdaq: QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging ...

Drill Program: 15,000 metres of drilling is planned for the year, with 2,600 metres completed by the end of Q1 2026. Primary Silver Revenues: 60% of the Company’s Q1 2026 revenues came from the sales ...

Seer, Inc. ( SEER) Q1 2026 Earnings Call May 13, 2026 4:30 PM EDT Good day, and welcome to Seer First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note this event is being ...

Daré Bioscience, Inc. ( DARE) Q1 2026 Earnings Call May 14, 2026 4:30 PM EDT [Operator Instructions] We will take our first question from the line of Kemp Dolliver from Brookline Capital Markets.

Jaylon Thompson profiles… Bill Duplissea! It’s the Royals ace replay man. “The first four innings, I’ve got to be 100%,” ...

Soundgarden might go on to much greater things, but for now they’re literally sleeping on top of one another in a room that ...

Cash position of €12.0 million as of March 31, 2026Shareholder loan agreement signed with Vester Finance on April 21, 2026, securing a cash runway until the beginning of Q2 2027BioChaperone®: ...